BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 314 filers reported holding BLUEBIRD BIO INC in Q2 2018. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $48,795,000 | -19.8% | 1,127,687 | +0.0% | 0.01% | -31.6% |
| Q3 2020 | $60,822,000 | -11.6% | 1,127,382 | -0.0% | 0.02% | -17.4% |
| Q2 2020 | $68,816,000 | +74.1% | 1,127,386 | +31.1% | 0.02% | +43.8% |
| Q1 2020 | $39,536,000 | -70.0% | 860,226 | -42.7% | 0.02% | -64.4% |
| Q4 2019 | $131,630,000 | -73.6% | 1,500,058 | -72.4% | 0.04% | -76.4% |
| Q3 2019 | $499,532,000 | -22.8% | 5,440,344 | +6.9% | 0.19% | -26.0% |
| Q2 2019 | $647,321,000 | -19.6% | 5,089,004 | -0.6% | 0.26% | -25.4% |
| Q1 2019 | $805,509,000 | +60.8% | 5,119,870 | +1.4% | 0.35% | +38.4% |
| Q4 2018 | $501,035,000 | +5.2% | 5,050,758 | +54.9% | 0.25% | +14.7% |
| Q3 2018 | $476,053,000 | +168.5% | 3,260,636 | +188.6% | 0.22% | +9.0% |
| Q2 2018 | $177,308,000 | +2.1% | 1,129,709 | +11.1% | 0.20% | -0.5% |
| Q1 2018 | $173,610,000 | – | 1,016,748 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,964,000 | $59,215,000 | 1.36% |
| Birchview Capital, LP | 75,500 | $2,276,000 | 1.35% |
| Camber Capital Management LP | 1,000,000 | $30,150,000 | 1.04% |
| Sessa Capital IM, L.P. | 875,000 | $26,381,000 | 1.02% |
| Bain Capital Life Sciences Investors, LLC | 538,179 | $16,226,000 | 0.92% |
| Tarsadia Capital, LLC | 100,000 | $3,015,000 | 0.81% |
| Bullseye Asset Management LLC | 67,872 | $2,046,000 | 0.76% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,304,246 | $39,323,000 | 0.58% |
| MANGROVE PARTNERS IM, LLC | 175,178 | $5,282,000 | 0.53% |
| Parametrica Management Ltd | 37,712 | $1,080,000 | 0.52% |